Trial Profile
A Phase II, Open-label Study of ONC201 in Adults With Recurrent High-grade Glioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Dordaviprone (Primary)
- Indications Astrocytoma; Glioma
- Focus Registrational; Therapeutic Use
- Sponsors Chimerix
- 11 Aug 2023 Planned End Date changed from 31 Jul 2023 to 30 Aug 2023.
- 11 Aug 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Aug 2023.
- 12 Jun 2023 Planned End Date changed from 15 May 2023 to 31 Jul 2023.